No Data
No Data
Fulcrum Therapeutics: Progress in Pociredir Trial Amidst Uncertainties and Market Challenges
Leerink Partners Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Piper Sandler Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Cuts Target Price to $6
Fulcrum Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $2 to $14
Fulcrum Therapeutics Analyst Ratings